MX368455B - Compuestos de tetrahidropirazolopirimidina. - Google Patents

Compuestos de tetrahidropirazolopirimidina.

Info

Publication number
MX368455B
MX368455B MX2014014497A MX2014014497A MX368455B MX 368455 B MX368455 B MX 368455B MX 2014014497 A MX2014014497 A MX 2014014497A MX 2014014497 A MX2014014497 A MX 2014014497A MX 368455 B MX368455 B MX 368455B
Authority
MX
Mexico
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
sle
toll
Prior art date
Application number
MX2014014497A
Other languages
English (en)
Other versions
MX2014014497A (es
Inventor
D Hawkins Lynn
Boivin Roch
Carlson Eric
Endo Atsushi
Hansen Hans
Ishizaka Sally
Mackey Matthew
Narayan Sridhar
Satoh Takashi
Schiller Shawn
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2014014497A publication Critical patent/MX2014014497A/es
Publication of MX368455B publication Critical patent/MX368455B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a distintas formas de realización de compuestos de tetrahidropirazolopirimidina que actúan como antagonistas o inhibidores de receptores similares a Toll 7 y/u 8, y con su uso en composiciones farmacéuticas eficaces para el tratamiento del lupus eritematoso sistémico (SLE) y la nefritis por lupus.
MX2014014497A 2012-05-31 2013-05-31 Compuestos de tetrahidropirazolopirimidina. MX368455B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (2)

Publication Number Publication Date
MX2014014497A MX2014014497A (es) 2015-06-02
MX368455B true MX368455B (es) 2019-10-03

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014497A MX368455B (es) 2012-05-31 2013-05-31 Compuestos de tetrahidropirazolopirimidina.

Country Status (34)

Country Link
US (5) US9126999B2 (es)
EP (1) EP2855476B1 (es)
JP (2) JP6285918B2 (es)
KR (2) KR102403007B1 (es)
CN (2) CN107344941B (es)
AR (1) AR091236A1 (es)
AU (2) AU2013267204B8 (es)
BR (1) BR112014030060B1 (es)
CA (1) CA2874445C (es)
CL (1) CL2014003278A1 (es)
CY (1) CY1122692T1 (es)
DK (1) DK2855476T3 (es)
ES (1) ES2709119T3 (es)
HR (1) HRP20181889T1 (es)
HU (1) HUE040562T2 (es)
IL (2) IL268013B2 (es)
JO (1) JO3407B1 (es)
LT (1) LT2855476T (es)
MX (1) MX368455B (es)
MY (1) MY172926A (es)
NZ (1) NZ703459A (es)
PE (2) PE20150220A1 (es)
PH (2) PH12014502660B1 (es)
PL (1) PL2855476T3 (es)
PT (1) PT2855476T (es)
RS (1) RS57977B1 (es)
RU (2) RU2677291C2 (es)
SG (1) SG11201407890VA (es)
SI (1) SI2855476T1 (es)
SM (1) SMT201800626T1 (es)
TW (1) TWI572606B (es)
UA (1) UA113440C2 (es)
WO (1) WO2013181579A2 (es)
ZA (1) ZA201409273B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3057948B1 (en) 2013-10-14 2018-03-14 Eisai R&D Management Co., Ltd. Selectively substituted quinoline derivatives
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
WO2015144801A1 (en) * 2014-03-27 2015-10-01 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
CN106573893B (zh) 2014-07-31 2020-06-09 巴斯夫欧洲公司 制备吡唑的方法
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
EP3294725B1 (en) 2015-05-11 2021-05-05 Basf Se Process for preparing 4-amino-pyridazines
WO2017004734A1 (zh) * 2015-07-03 2017-01-12 中国农业大学 苄基腙类化合物及其制备方法与应用
PE20181539A1 (es) * 2016-02-02 2018-09-26 Basf Se Proceso de hidrogenacion catalitico para preparar pirazoles
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) * 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018024644A1 (en) * 2016-08-02 2018-02-08 Solvay Sa Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use
CN115215886B (zh) * 2016-09-09 2024-10-11 诺华股份有限公司 作为内体Toll样受体抑制剂的化合物及组合物
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
TW201900647A (zh) * 2017-05-18 2019-01-01 大陸商江蘇恒瑞醫藥股份有限公司 雜芳基并吡唑類衍生物、其製備方法及其在醫藥上的應用
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
US11130756B2 (en) 2017-08-04 2021-09-28 Bristol-Myers Squibb Company [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
EA202091477A1 (ru) * 2017-12-15 2020-10-28 Бристол-Маерс Сквибб Компани Замещенные соединения простых индольных эфиров
EA202091484A1 (ru) * 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения
JP7291145B2 (ja) * 2017-12-19 2023-06-14 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効な置換されたインドール化合物
CA3085761A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists
WO2019126081A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
AU2018393003A1 (en) 2017-12-20 2020-08-06 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
EP3728264B1 (en) * 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Diazaindole compounds
EA202091480A1 (ru) 2017-12-20 2020-11-06 Бристол-Маерс Сквибб Компани Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
WO2019123294A2 (en) 2017-12-22 2019-06-27 Novartis Ag Novel uses of pyrazolo piperidine derivatives
WO2019122164A1 (en) * 2017-12-22 2019-06-27 Solvay Sa Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof
US20210238136A1 (en) * 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
CN112654620B (zh) * 2018-09-06 2023-08-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型吡唑并吡啶化合物
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
EP3877388B1 (en) * 2018-11-09 2023-07-26 F. Hoffmann-La Roche AG 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus
IL285315B2 (en) * 2019-02-07 2025-12-01 Beigene Ltd Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
US12187723B2 (en) 2019-05-09 2025-01-07 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN112321590A (zh) * 2019-08-02 2021-02-05 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
CN114761404B (zh) 2019-10-01 2025-02-21 百时美施贵宝公司 经取代的双环杂芳基化合物
JP7545467B2 (ja) 2019-10-04 2024-09-04 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
JPWO2021112251A1 (es) * 2019-12-06 2021-06-10
EP4323369A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Thienopyrrole compounds
GB202107932D0 (en) * 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
JP2024533374A (ja) 2021-09-10 2024-09-12 ギリアード サイエンシーズ， インコーポレイテッド チエノピロール化合物

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
AU3320602A (en) 2000-12-06 2002-06-18 Aventis Pharma Gmbh Guanidine and amidine derivatives as factor xa inhibitors
PT1368355E (pt) * 2001-03-14 2006-09-29 Gruenenthal Gmbh Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
ES2247527T3 (es) 2002-04-26 2006-03-01 Pfizer Prod Inc Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
EP1534707B9 (en) 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
ATE372324T1 (de) 2003-04-30 2007-09-15 Inst For Pharm Discovery Inc Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
AU2004248160B2 (en) 2003-06-12 2010-05-27 Merck Sharp & Dohme Corp. Prodrugs of mitotic kinesin inhibitors
EP2236131A3 (en) 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
JP2007536238A (ja) 2004-05-04 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド エストロゲン受容体で活性を持つ化合物
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
KR20070085340A (ko) 2004-10-12 2007-08-27 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물
CA2588766A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
EP1841415A2 (en) 2005-01-20 2007-10-10 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006129583A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US20090042856A1 (en) 2005-09-01 2009-02-12 Astellas Pharma Inc Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
JP5498703B2 (ja) 2006-01-23 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
WO2007102531A1 (ja) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited 併用薬
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007139795A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538309A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
EA200802417A1 (ru) 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
RU2450004C2 (ru) 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CN101889014A (zh) * 2007-11-15 2010-11-17 卫材R&D管理有限公司 富含对映体的咪唑并吖庚因酮化合物
BRPI0820701A2 (pt) * 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8338392B2 (en) 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2009111207A1 (en) 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US9066951B2 (en) 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
CA2727245A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of faah
AU2009257795A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of FAAH
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
JP5433691B2 (ja) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
JP5698666B2 (ja) 2008-08-04 2015-04-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆａａｈの阻害剤として有用なオキサゾール誘導体
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
KR101354763B1 (ko) 2008-08-25 2014-01-22 아이알엠 엘엘씨 헷지호그 경로 조절제
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
EP2352725A1 (en) 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
CA2749114C (en) 2009-01-19 2013-12-17 Daiichi Sankyo Company, Limited Heteroatom-containing cyclic compound
LT2403499T (lt) 2009-03-02 2020-01-10 Stemsynergy Therapeutics, Inc. Būdai ir kompozicijos, skirti panaudoti vėžio gydymui ir wnt sąlygotų poveikių ląstelėje sumažinimui
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010141696A1 (en) 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
TWI531571B (zh) 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
EP2523561A4 (en) 2009-12-22 2013-06-05 Merck Sharp & Dohme 7,8-DIHYDRO-1H-IMIDAZO [2,1-B] PURINE-4 (5H) -ONE DERIVATIVES AND METHOD OF USE
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
EP2528603A4 (en) 2010-01-28 2013-09-04 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN AND OTHER DISPLAYS
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
US9040714B2 (en) 2010-04-05 2015-05-26 Mannkind Corporation IRE-1α inhibitors
WO2011133447A1 (en) 2010-04-22 2011-10-27 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
CA2811989A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Diarylpyridine anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
SG11201404667XA (en) 2012-02-13 2014-09-26 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)

Also Published As

Publication number Publication date
AU2017204586B2 (en) 2018-11-08
JO3407B1 (ar) 2019-10-20
JP6619829B2 (ja) 2019-12-11
MX2014014497A (es) 2015-06-02
PE20150220A1 (es) 2015-02-14
IL268013A (en) 2019-09-26
KR102403007B1 (ko) 2022-05-31
AU2013267204A1 (en) 2015-01-29
UA113440C2 (xx) 2017-01-25
CN107344941B (zh) 2020-04-21
BR112014030060A2 (pt) 2017-09-12
RS57977B1 (sr) 2019-01-31
PL2855476T3 (pl) 2019-02-28
WO2013181579A2 (en) 2013-12-05
RU2677291C2 (ru) 2019-01-16
SG11201407890VA (en) 2014-12-30
CN104507939B (zh) 2017-07-25
NZ703459A (en) 2016-09-30
CY1122692T1 (el) 2020-07-31
ZA201409273B (en) 2016-05-25
US10640500B2 (en) 2020-05-05
LT2855476T (lt) 2019-01-10
US9446046B2 (en) 2016-09-20
SMT201800626T1 (it) 2019-01-11
KR20150016366A (ko) 2015-02-11
TWI572606B (zh) 2017-03-01
IL235986B (en) 2019-11-28
PH12014502660A1 (en) 2015-01-21
US9126999B2 (en) 2015-09-08
IL268013B1 (en) 2024-01-01
DK2855476T3 (en) 2018-12-17
RU2018146532A3 (es) 2019-06-21
CA2874445A1 (en) 2013-12-05
PH12019500522A1 (en) 2020-11-04
KR102268155B1 (ko) 2021-06-24
EP2855476A2 (en) 2015-04-08
RU2018146532A (ru) 2019-01-31
AU2013267204B2 (en) 2017-04-06
US9850242B2 (en) 2017-12-26
US20130324547A1 (en) 2013-12-05
SI2855476T1 (sl) 2018-12-31
BR112014030060B1 (pt) 2022-05-31
RU2733959C2 (ru) 2020-10-08
TW201402575A (zh) 2014-01-16
AU2013267204A8 (en) 2017-04-13
CA2874445C (en) 2022-06-21
ES2709119T3 (es) 2019-04-15
JP2015523981A (ja) 2015-08-20
RU2014154397A (ru) 2016-07-27
IL268013B2 (en) 2024-05-01
JP2018087221A (ja) 2018-06-07
HUE040562T2 (hu) 2019-03-28
PH12014502660B1 (en) 2020-02-14
CL2014003278A1 (es) 2015-06-12
PE20190973A1 (es) 2019-07-09
AU2017204586A1 (en) 2017-07-27
HK1203498A1 (en) 2015-10-30
AU2013267204B8 (en) 2017-04-13
US20200347050A1 (en) 2020-11-05
MY172926A (en) 2019-12-14
JP6285918B2 (ja) 2018-02-28
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
CN107344941A (zh) 2017-11-14
US20160339032A1 (en) 2016-11-24
EP2855476B1 (en) 2018-09-05
KR20210076210A (ko) 2021-06-23
WO2013181579A3 (en) 2014-03-27
HRP20181889T1 (hr) 2019-01-11
CN104507939A (zh) 2015-04-08
AR091236A1 (es) 2015-01-21
US20160030430A1 (en) 2016-02-04
IL235986A0 (en) 2015-02-01
PT2855476T (pt) 2018-12-03

Similar Documents

Publication Publication Date Title
PH12019500522A1 (en) Tetrahydropyrazolopyrimidine compounds
MX2016004632A (es) Compuestos de quinolina selectivamente sustituida.
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
IN2014DN10576A (es)
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MY173521A (en) Trpv4 antagonists
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
IN2013MU03641A (es)
MA39824A (fr) Composés azole amido-substitués
UA116207C2 (uk) Виділена тверда форма моногідрохлориду анамореліну та фармацевтична композиція, що її містить

Legal Events

Date Code Title Description
FG Grant or registration